| Similar Articles |
|---|
 |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy.   |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too. |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
August 31, 2007
Rich Smith |
A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it? |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news. |
The Motley Fool
April 21, 2004
Ben McClure |
Nortel's Big What If Will the telecom equipment maker Nortel Networks get through its accounting issues unscathed? |
The Motley Fool
March 10, 2006
Rich Duprey |
Blockbuster's Reel Cash Flow Woes A change in the movie rental firm's accounting will harm its cash flows. Wall Street may want to ignore Blockbuster's condition, but you don't have to. |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
May 19, 2006
Jim Mueller |
Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
The Motley Fool
March 21, 2005
Rich Duprey |
Inamed Buoyant on Medicis Buyout Breast-implant maker Inamed will be acquired in a $2.8 billion deal with skin-care pharmaceutical Medicis. Inamed investors should now decide whether they want to be a part of Medicis or enjoy the profits realized from the offer. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
